Close Menu

The drug industry's main lobbying group is kicking out members that don't spend enough on developing new products.

According to new rules from the Pharmaceutical Research and Manufacturers of America that went into effect this week, in order to remain members, drug firms  will have to spend at least 10 percent of their sales on global research and development over three years. They will also need to spend at least $200 million per year on R&D.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.